Ze-Hong Miao was awarded a B.S. degree in medicine by the West China University of Medical Sciences, Chengdu, China, in 1988, an M.S. degree of medicine in pharmacology by the Chinese Academy of Medical Sciences and Peking Union Medical College (PUMC) in 1993, and a Ph.D. degree in pharmacology by the Chinese Academy of Sciences, Beijing, China in 2003. He was trained as a Visiting Fellow at the National Cancer Institute of the National Institutes of Health between 2004 and 2006. He served as an Associate Professor from 2003 to 2007 and has been working as a Full Professor since 2007 at the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences. Dr. Miao is now running a laboratory that is focused on new anticancer drugs/compounds research and development and their mechanistic investigations, with an emphasis on tumor hypoxia, DNA damage and repair interference, and drug resistance. He has submitted 12 patent applications (national or international) and published over 50 SCI peer-reviewed papers. Dr. Miao has many publications, including “MFTZ-1 reduces constitutive and inducible HIF-1a accumulation and VEGF secretion independent of its topoisomerase II inhibition” Journal of Cellular and Molecular Medicine, 2010, “Poly (ADP-ribose) polymerase inhibitors as promising cancer therapeutics” Acta Pharmacologica Sinica, 2010, and “c-Jun protects hypoxia-inducible factor-1a from degradation via its oxygen-dependent degradation domain in a nontranscriptional manner” Cancer Research, 2009.
Biography Updated on 9 December 2010